Structure Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Structure Therapeutics (GPCR).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

3S.Buy

12Buy

Consensus RatingBuy# Analysts15Avg. Consensus PT$98Upside to Avg. PT+378.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Citizens	Jonathan Wolleben	Maintained	Market Outperform	$110
Aug 7, 2026	Citigroup	Samantha Semenkow	PT Cut	Buy	$100→$97
Aug 7, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$113→$110
Jun 11, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$100→$70
Apr 27, 2026	Canaccord Genuity	Edward Nash	Initiate	Buy	$101
Mar 16, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$114→$100
Mar 2, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Raise	Buy	$90→$114
Feb 27, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$120→$113
Jan 22, 2026	JP Morgan	Hardik Parikh	PT Raise	Overweight	$65→$105
Jan 20, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$90→$140
Dec 19, 2025	HC Wainwright & Co.	Ananda Ghosh	PT Raise	Buy	$60→$90
Dec 12, 2025	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$120→$125
Dec 12, 2025	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$87→$120
Dec 11, 2025	Jefferies	Chris Howerton	PT Raise	Buy	$79→$125
Dec 9, 2025	Citigroup	Samantha Semenkow	PT Raise	Buy	$60→$100
Dec 9, 2025	Stifel	Annabel Samimy	PT Raise	Buy	$50→$90
Dec 9, 2025	Clear Street	Kaveri Pohlman	PT Raise	Buy	$61→$99
Aug 7, 2025	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$75→$60
Aug 7, 2025	Guggenheim	Seamus Fernandez	PT Cut	Buy	$92→$90
Aug 7, 2025	JMP Securities	Jonathan Wolleben	PT Cut	Market Outperform	$89→$87

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.

Benzinga Newsdesk

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ratings page: CHEF, NAVN, INTC, HOOD, GPCR, OTLK, ORCL.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $70.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Buy rating and announces Price Target of $101.

Benzinga Newsdesk

Structure Therapeutics Inc

Structure Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

People Also Watch

People Also Watch

Structure Therapeutics Inc

Structure Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCitizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

PROCitigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

PROCitizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

PROHC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

PROCanaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

People Also Watch

People Also Watch

PRO
Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101